lung cancer
-
INVEST Pitch Perfect Spotlight: How Prana Thoracic Can Help Treat Lung Cancer Sooner
Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.
-
Noah Medical Rakes In $150M for Its Robotic Lung Biopsy Platform
Medical robotics startup Noah Medical recently closed a $150 million Series B funding round. The company’s robotic platform, called the Galaxy System, was designed to help physicians find, biopsy and diagnose lung cancer lesions with more ease and confidence.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Bio Startup Scorpion Partners With Pierre Fabre for Trials of Targeted Lung Cancer Drugs
Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature.
-
BioNTech Puts Up $200M to Partner With OncoC4 in Cancer Immunotherapy
BioNTech is expanding its cancer immunotherapy scope by partnering with OncoC4 on clinical testing of its lead drug. The antibody was designed to offer a safety edge over other CTLA-4-blocking drugs it’s on track for a Phase 3 test in non-small cell lung cancer.
-
Devices & Diagnostics, BioPharma
Tumor-Zapping Device Scores in Pivotal Study, Sends Shares of Novocure Soaring
Novocure’s electrical field-producing medical device, in combination with standard drug therapies, improved overall survival in a pivotal study that enrolled patients with advanced non-small cell lung cancer. The medtech company now plans to seek regulatory approvals.
-
Amgen’s Phase 3 win in lung cancer puts pressure on Mirati bid for speedy FDA nod
Amgen said its drug Lumakras met the main goal of a Phase 3 study in non-small cell lung cancer driven by a particular genetic mutation. The pharmaceutical giant offered no specifics, but the results set the stage for an interesting regulatory race with a rival drug from Mirati Therapeutics
-
AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer
On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2.
-
BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche
Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as a treatment for certain lung cancers. Recently reported preliminary data suggest the small molecule could have advantages over currently available drugs in the same class from rivals Pfizer and Roche.
-
MedCity Influencers, Devices & Diagnostics
Giving physicians the power of precision imaging for lung disease
Confocal laser endomicroscopy is an imaging technology that delivers visibility into cellular activity that enables physicians to assess areas of concern in cases where conventional disease screening returns ambiguous results.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Closely watched Roche drug fails a second pivotal test in lung cancer
Roche reported that its drug tiragolumab failed to achieve one of two main goals of a Phase 3 study in non-small cell lung cancer. The antibody is designed to block TIGIT, a checkpoint protein that has been a hot target for pharmaceutical companies looking for a way to broaden the reach of cancer immunotherapy.
-
Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene’s antibody drug.
-
Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs
Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics’ FateControl technology ensures that more of an ADC’s drug payload reaches the tumor, and CEO Alex Nichols is steering the startup out of stealth with $103 million and a lead program in lung cancer.
-
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
-
EMD Serono targeted therapy gets speedy FDA approval for lung cancer
EMD Serono’s Tepmetko is one of a number of targeted cancer therapies that have passed FDA muster in the past year. The decision sets up the German company’s pill for head-to-head competition with a Novartis drug targeting the same genetic signature.
-
MedCity Pivot Podcast: A conversation with AstraZeneca’s U.S. Head of Medical Affairs Oncology
In this episode of MedCity Pivot podcast, we talk with Camille Hertzka, AstraZeneca’s U.S. Head of Medical Affairs Oncology, about the clinical study findings on lung cancer presented at ESMO and the rapidly changing landscape for lung cancer treatment.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
